Compare KRMD & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | SENS |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.3M | 301.2M |
| IPO Year | 2019 | 2014 |
| Metric | KRMD | SENS |
|---|---|---|
| Price | $4.10 | $6.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.50 | ★ $18.38 |
| AVG Volume (30 Days) | 116.5K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,127,366.00 | $16,389,000.00 |
| Revenue This Year | $20.32 | $74.15 |
| Revenue Next Year | $17.37 | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | 19.85 |
| 52 Week Low | $2.68 | $0.41 |
| 52 Week High | $6.61 | $8.75 |
| Indicator | KRMD | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 54.87 |
| Support Level | $3.87 | $5.41 |
| Resistance Level | $4.34 | $8.55 |
| Average True Range (ATR) | 0.17 | 0.47 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 34.09 | 83.98 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.